Supplementary Materials

The PDF file includes:

  • Materials and Methods
  • Fig. S1. In vitro OX40L bioactivity and in vivo cellular and tissue expression of OX40L after intratumoral mRNA administration.
  • Fig. S2. Characterization of multiple syngeneic tumor models for responses to systemic checkpoint blockade therapies.
  • Fig. S3. In vitro bioactivity of cytokine targets and in vivo expression of cytokine targets in tumor models.
  • Fig. S4. Tolerability and dose-dependent efficacy of intratumoral mRNA therapy.
  • Fig. S5. Induction of cytokines by multi-mRNA treatment.
  • Fig. S6. Differentially expressed immune-related transcripts in control mRNA–treated tumors.
  • Fig. S7. Activation status of DCs and T cells in response to local treatment with control mRNA.
  • Fig. S8. Induction of granulocyte infiltration by multi-mRNA treatment and granulocyte contribution to antitumor efficacy.
  • Fig. S9. DC profile in TdLN of mRNA-treated tumors and in vitro response of BMDCs to cytokines.
  • Fig. S10. Induction of lymphocyte activation and remodeling of the TME by multi-mRNA treatment.
  • Fig. S11. Overall transcript and costimulation focused transcript changes, and remodeling of the TME induced by multi-mRNA treatment.
  • Fig. S12. Local mRNA therapy: Protein expression by alternate routes of administration, resistance to secondary tumor challenge, and antitumor memory.
  • Fig. S13. Improved antitumor efficacy with combination of triplet mRNA and checkpoint blockade.
  • Fig. S14. Response of human MDMs to IL-36γ.
  • Table S1. Measurement of protein abundance in tumors after mRNA treatment and calculation of recombinant protein dosing.
  • Table S2. Proteins, antibodies, and controls for in vivo dosing.
  • Table S3. Probes in NanoString Plus Panel.
  • Table S4. Flow cytometry staining antibodies.
  • Reference (55)

[Download PDF]

Other Supplementary Material for this manuscript includes the following: